President Trump’s recent appointment of Kyle Diamantas as acting FDA commissioner following Marty Makary’s mid-May 2026 resignation has positioned the deputy commissioner for food as the clear frontrunner in trader consensus for the permanent role. Diamantas, a former corporate attorney with oversight of the Human Foods Program and ties to the administration’s Make America Healthy Again priorities, now leads the agency on an interim basis while Health and Human Services Secretary Robert F. Kennedy Jr. conducts the search for a Senate-confirmed successor. This development has elevated Diamantas’s implied probability above other previously discussed names, including former commissioner Stephen Hahn and officials such as Brett Giroir, Sara Brenner, and Grace Graham. The 23.6 percent chance of no announcement by year-end reflects uncertainty around confirmation timelines and potential shifts in White House preferences during the ongoing selection process.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhậtKyle Diamantas 54%
Stephen Hahn 4%
Brett Giroir 3.9%
Sara Brenner 3.3%
MỚI
MỚI
Dec 31, 2026
Kyle Diamantas
54%
Stephen Hahn
4%
Brett Giroir
4%
Grace Graham
3%
Sara Brenner
3%
No announcement by December 31
16%
Kyle Diamantas 54%
Stephen Hahn 4%
Brett Giroir 3.9%
Sara Brenner 3.3%
MỚI
MỚI
Dec 31, 2026
Kyle Diamantas
$1,525 KL.
54%
Stephen Hahn
$976 KL.
4%
Brett Giroir
$1,510 KL.
4%
Grace Graham
$1,893 KL.
3%
Sara Brenner
$849 KL.
3%
No announcement by December 31
$533 KL.
16%
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.President Trump’s recent appointment of Kyle Diamantas as acting FDA commissioner following Marty Makary’s mid-May 2026 resignation has positioned the deputy commissioner for food as the clear frontrunner in trader consensus for the permanent role. Diamantas, a former corporate attorney with oversight of the Human Foods Program and ties to the administration’s Make America Healthy Again priorities, now leads the agency on an interim basis while Health and Human Services Secretary Robert F. Kennedy Jr. conducts the search for a Senate-confirmed successor. This development has elevated Diamantas’s implied probability above other previously discussed names, including former commissioner Stephen Hahn and officials such as Brett Giroir, Sara Brenner, and Grace Graham. The 23.6 percent chance of no announcement by year-end reflects uncertainty around confirmation timelines and potential shifts in White House preferences during the ongoing selection process.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Thị trường mở: May 12, 2026, 7:59 PM ET
Khối lượng
$7,286Ngày kết thúc
Dec 31, 2026Thị trường mở
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.President Trump’s recent appointment of Kyle Diamantas as acting FDA commissioner following Marty Makary’s mid-May 2026 resignation has positioned the deputy commissioner for food as the clear frontrunner in trader consensus for the permanent role. Diamantas, a former corporate attorney with oversight of the Human Foods Program and ties to the administration’s Make America Healthy Again priorities, now leads the agency on an interim basis while Health and Human Services Secretary Robert F. Kennedy Jr. conducts the search for a Senate-confirmed successor. This development has elevated Diamantas’s implied probability above other previously discussed names, including former commissioner Stephen Hahn and officials such as Brett Giroir, Sara Brenner, and Grace Graham. The 23.6 percent chance of no announcement by year-end reflects uncertainty around confirmation timelines and potential shifts in White House preferences during the ongoing selection process.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Khối lượng
$7,286Ngày kết thúc
Dec 31, 2026Thị trường mở
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...President Trump’s recent appointment of Kyle Diamantas as acting FDA commissioner following Marty Makary’s mid-May 2026 resignation has positioned the deputy commissioner for food as the clear frontrunner in trader consensus for the permanent role. Diamantas, a former corporate attorney with oversight of the Human Foods Program and ties to the administration’s Make America Healthy Again priorities, now leads the agency on an interim basis while Health and Human Services Secretary Robert F. Kennedy Jr. conducts the search for a Senate-confirmed successor. This development has elevated Diamantas’s implied probability above other previously discussed names, including former commissioner Stephen Hahn and officials such as Brett Giroir, Sara Brenner, and Grace Graham. The 23.6 percent chance of no announcement by year-end reflects uncertainty around confirmation timelines and potential shifts in White House preferences during the ongoing selection process.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhật
Cẩn thận với liên kết bên ngoài.
Cẩn thận với liên kết bên ngoài.
Câu hỏi thường gặp